OPTICAL BIOSENSOR FOR THE EARLY DETECTION OF BREAST CANCER

用于乳腺癌早期检测的光学生物传感器

• 批准号: 7368159
• 负责人: John Ernest Shively
• 金额: $ 0.65万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7368159
• 关键词: OPTICAL; BIOSENSOR; EARLY; DETECTION; BREAST

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In the first stage we propose to determine if the measurement of proteins (specifically CEA) secreted by the breast captured in a nitrocellulose filter can be used in detecting breast cancer. For that purpose we will obtain samples from nipple secretions in nitrocellulose paper from patients requiring a breast biopsy to determine the sensitivity and specificity of the assay. In a second stage an optical biosensor that has been optimized for the detection of CEA will be used to detect fluorescent labeled antibodies directed against CEA found in the serum and breast secretions. The tumor marker carcinoembryonic antigen (CEA) will be used as an early marker for breast cancer in blood and nipple secretions as a model system. Ultimately, the biosensor will be a handheld device that can be used to test minute amounts of blood or secretions in a point of service context. The availability of such a device should allow earlier and more convenient testing for CEA and, eventually, for other tumor markers.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。在第一阶段中，我们建议确定是否可以使用在硝酸纤维素过滤器中捕获的乳腺分泌的蛋白质（特别是CEA）的测量来检测乳腺癌。为此，我们将从需要进行乳腺活检的患者的乳头分泌物中获取硝酸纤维素纸样本，以确定该检测的灵敏度和特异性。在第二阶段中，已经优化用于检测CEA的光学生物传感器将用于检测针对血清和乳腺分泌物中发现的CEA的荧光标记抗体。肿瘤标志物癌胚抗原（CEA）将作为乳腺癌的早期标志物，在血液和乳头分泌物中作为模型系统。最终，生物传感器将成为一种手持式设备，可用于在服务点测试微量血液或分泌物。这种设备的可用性应该允许更早和更方便地检测CEA，并最终检测其他肿瘤标志物。